Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The current review covers extant literature on pharmacotherapy for core symptoms of autism. The core symptoms of autism include impairments in social interaction and communication, as well as the presence of restricted and repetitive behaviors. There are no known efficacious treatments for the core social symptoms, although effects on repetitive behaviors are indicated with some data. While studies of fenfluramine, secretin, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics. Newer lines of research, including cholinergic and glutamatergic agents and oxytocin, will be of considerable interest in the future. However, research on the treatment of core symptoms is plagued by limitations in study design, statistical power, and other issues inherent to the study of treatments for autism (e.g., heterogeneity of the disorder) that continue to prevent the elucidation of efficacious treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318179964f · Cited by 3,399
Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS)
Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02408436 · Cited by 2,432
Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity
SCAHILL, L., RIDDLE, M. A., McSWIGGIN-HARDIN, M., ORT, S. I., KING, R. A., GOODMAN, W. K., CICCHETTI, D., & LECKMAN, J. F. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00023 · Cited by 2,045
Comorbid psychiatric disorders in children with autism: interview development and rates of disorders
Leyfer, O. T., Folstein, S. E., Bacalman, S., Davis, N. O., Dinh, E., Morgan, J., Tager-Flusberg, H., & Lainhart, J. E. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0123-0 · Cited by 1,637
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Insel, T. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.03.005 · Cited by 1,044
Oxytocin Increases Retention of Social Cognition in Autism
Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., Anagnostou, E., & Wasserman, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.030 · Cited by 693 · cited 1×
“Comprehension of affective qualities of speech was also evaluated as an outcome variable [81].”
Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689 · cited 1×
“Fifteen adults with ASD were challenged with an infusion of synthetic oxytocin (pitocin) in a placebo-controlled crossover study [80].”
Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 2×
“Studies of MGluR in fragile X, and rapamycin in tuberous sclerosis, are examples, in the ability to test whether methylation status moderates efficacy [84], and the ability to correct mammalian target of rapamycin (mTOR) pathway abnormalities, respectively [91].”
Research works printed but not linked: 68
- American Psychological Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington: American Psychiatric Association; 2000.
- Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33(5):527–34. · DOI · Paper page
- Siegel M, Beaulieu AA. Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice. J Autism Dev Disord. 2012;42(8):1592–605. · DOI
- Lecavalier L, Aman MG, Hammer D, Stoica W, Mathews GL. Factor analysis of the Nisonger child behavior rating form in children with autism spectrum disorders. J Autism Dev Disord. 2004;34(6):709–21. · DOI
- Farmer CA, Aman MG. Aripiprazole for the treatment of irritability associated with autism. Expert Opin Pharmacother. 2011;12(4):635–40. · DOI
- Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007;9(5):343–54. · DOI
- Doyle CA, McDougle CJ. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother. 2012;13(11):1615–29. · DOI · Paper page
- Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr. 1996;8(4):348–54. · DOI · Paper page
- Geller E, Ritvo ER, Freeman BJ, Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med. 1982;307(3):165–9. · DOI · Paper page
- Ritvo ER, Freeman BJ, Yuwiler A, Geller E, Schroth P, Yokota A, et al. Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull. 1986;22(1):133–40.
- Campbell M, Adams P, Small AM, Curren EL, Overall JE, Anderson LT, et al. Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27(4):434–9. · DOI
- Stern LM, Walker MK, Sawyer MG, Oades RD, Badcock NR, Spence JG. A controlled crossover trial of fenfluramine in autism. J Child Psychol Psychiatry. 1990;31(4):569–85. · DOI
- Leventhal BL, Cook EH, Morford M, Ravitz AJ, Heller W, Freedman DX. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatr Clin Neurosci. 1993;5(3):307–15. · DOI
- Sherman J, Factor DC, Swinson R, Darjes RW. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord. 1989;19(4):533–43. · DOI
- Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother. 2006;40(6):1086–95. · DOI · Paper page
- Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res. 1995;58(3):203–15. · DOI
- Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9(1):9–15.
- Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003495. · DOI · Paper page
- Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62(7):530–4. · DOI · Paper page
- Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol. 2006;9(2):209–13. · DOI · Paper page
- Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35(4):990–8. · DOI · Paper page
- Yasuhara A. Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD). Brain Dev. 2010;32(10):791–8. · DOI · Paper page
- Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31(2):175–81. · DOI · Paper page
- Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2006;21(6):363–7. · DOI · Paper page
- Aman M, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485–91.
- McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142–8. · DOI · Paper page
- Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):E634–41. · DOI · Paper page
- Aman MG, Tasse MJ, Rojahn J, Hammer D. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil. 1996;17(1):41–57. · DOI · Paper page
- Scahill L, Hallet T, Aman M, Arnold LE, McDougle C, McCracken J, et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord. 2013;24(3):739–46. · DOI · Paper page
- Sparrow S, Balla D, Cicchetti D. Vineland adaptive behavior scales: survey form manual. Circle Pines: American Guidance Service; 1984.
- Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl). 2012;223(2):237–45. · DOI
- Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–9. · DOI · Paper page
- Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72(9):1270–6. · DOI · Paper page
- Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50(6):441–7. · DOI · Paper page
- Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl. 1978;271:5–27. · DOI · Paper page
- Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21(4):440–4. · DOI · Paper page
- Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30(3):582–9. · DOI · Paper page
- McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001–8. · DOI · Paper page
- Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol. 2006;16(1–2):181–6. · DOI · Paper page
- Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008;17(4):787–801. · DOI · Paper page
- Chez M, Buchanan T, Becker M, Kessler J, Aimonovitch M, Mrazek S. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol. 2003;1(2):83–8.
- Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002;12(3):237–41. · DOI · Paper page
- Doyle RL, Frazier J, Spencer TJ, Geller D, Biederman J, Wilens T. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006;9(3):543–9. · DOI · Paper page
- Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, et al. An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2011;21(4):353–7. · DOI · Paper page
- Niederhofer H. Treating autism pharmacologically: also tacrine might improve symptomatology in some cases. J Child Neurol. 2007;22(8):1054. (author reply 1054–5). · DOI
- Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19(3):165–9. · DOI · Paper page
- Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16(5):621–9. · DOI · Paper page
- Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ. 2002;325(7377):1422. · DOI · Paper page
- McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry. 2005;66(Suppl 10):9–18.
- Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56(1):21–7. · DOI · Paper page
- Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of d-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161(11):2115–7. · DOI · Paper page
- King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658–65. · DOI · Paper page
- Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191(1):141–7. · DOI · Paper page
- Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574–9. · DOI · Paper page
- Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):517–24. · DOI · Paper page
- Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clini Psychopharmacol. 2007;27(3):317–8. · DOI · Paper page
- Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21(6):565–9. · DOI · Paper page
- Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with Autism. Biol Psychiatry. 2012;71(11):956–61. · DOI · Paper page
- Chadman KK, Guariglia SR, Yoo JH. New directions in the treatment of autism spectrum disorders from animal model research. Expert Opin Drug Discov. 2012;7(5):407–16. · DOI
- Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67(7):692–4. · DOI · Paper page
- Sandler AD, Bodfish JW. Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr. 2000;21(5):347–50. · DOI · Paper page
- Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, et al. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008;69(10):1513–28. · DOI · Paper page
- Aman MG, Novotny S, Samango-Sprouse C, Lecavalier L, Leonard E, Gadow KD, et al. Outcome measures for clinical drug trials in autism. CNS Spectr. 2004;9(1):36–47. · DOI · Paper page
- Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659–85. · DOI · Paper page
- Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30(3):205–23. · DOI · Paper page
- Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT, et al. Children’s Yale-Brown obsessive compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(9):1114–23. · DOI · Paper page
- Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27(1):1–5. · DOI · Paper page
- Scahill L, McCracken JT, Bearss K, Robinson F, Hollander E, King B, et al. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. J Autism Dev Disord. 2012;42(3):432–40. · DOI
Cited by
Lai, M.-C., Lombardo, M. V., & Baron-Cohen, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61539-1 · Cited by 2,371
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Atzil, S., Gao, W., Fradkin, I., & Barrett, L. F. (2018) · Nature Human Behaviour · doi:10.1038/s41562-018-0384-6 · Cited by 415
Autism spectrum disorder in fragile X syndrome: cooccurring conditions and current treatment
Kaufmann, W. E., Kidd, S. A., Andrews, H. F., Budimirovic, D. B., Esler, A., Haas-Givler, B., Stackhouse, T., Riley, C., Peacock, G., Sherman, S. L., et al. (2017) · PEDIATRICS · doi:10.1542/peds.2016-1159f · Cited by 268
Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review
Jobski, K., Höfer, J., Hoffmann, F., & Bachmann, C. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12644 · Cited by 263
Metadata
- Authors
- Farmer, C., Thurm, A., & Grant, P.
- Venue
- Drugs
- Published
- 2013-03
- Volume
- 73
- Issue
- 4
- Pages
- 303-314
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2018851253
- Cited by
- 115
- References
- 24
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research. https://app.cochat.ai/papers/10.1007/s40265-013-0021-7
- The paper
- Farmer, C., Thurm, A., & Grant, P. (2013). Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research. Drugs. https://doi.org/10.1007/s40265-013-0021-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.